Pressure BioSciences Inc. (PBIO) Issues Quarterly Earnings Results, Misses Estimates By $1.17 EPS

Pressure BioSciences Inc. (OTCMKTS:PBIO) released its earnings results on Tuesday. The company reported ($2.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($1.17), reports.

Pressure BioSciences (PBIO) opened at $3.90 on Tuesday. Pressure BioSciences has a 12-month low of $0.70 and a 12-month high of $11.52.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thestockobserver.com/2017/11/14/pressure-biosciences-inc-pbio-issues-quarterly-earnings-results-misses-estimates-by-1-17-eps.html.

Separately, ValuEngine downgraded Pressure BioSciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd.

Pressure BioSciences Company Profile

Pressure BioSciences, Inc is focused on solving the problems inherent in biological sample preparation. The Company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, such as approximately 35,000 pounds per square inch (psi) or greater to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

Earnings History for Pressure BioSciences (OTCMKTS:PBIO)

Receive News & Ratings for Pressure BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply